On the contrary, results from a retrospective study involving 530 previously treated NSCLC patients treated with nivolumab showed that KRAS status was not a reliable predictor of immunotherapy efficacy in terms of response and survival rates [22]. Here, KRAS is linked to non-small cell lung carcinoma.